This editorial refers to ‘Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves’†, by J.B. Kuramatsu et al., on page 1709. Intracranial haemorrhage (ICH) is the most feared complication of oral anticoagulation for patients on vitamin K antagonists (VKAs). This concerns mostly patients with atrial fibrillation or venous thrombo-embolism, or those carrying mechanical heart valves. The incidence of VKA-associated ICH is ∼0.7% per year with atrial fibrillation1 and 0.5% per year in the patients with a mechanical heart valve.2 Although often fatal, VKA-induced ICH can be effectively treated with a reversal strategy using prothrombin concentrate complex. Yet, the surviving patients are at risk for thrombo-embolic complications and, thus, in need of resumption of therapeutic anticoagulation, either with heparin followed by a VKA, or with just a VKA. Alternatively, non-vitamin K oral anticoagulants (NOACs) could be chosen, since they induce much less ICH3, but this only applies for patients with atrial fibrillation or venous thrombo-embolism, and not for carriers of mechanical heart valves.4 The question remains, however, of when to restart therapeutic anticoagulation in mechanical heart valve patients surviving ICH. Proper studies on the subject are scarce5,6 and, thus, guidelines do not address this issue specifically.4,7,8 Therefore, the area is somewhat data free. In this issue of the journal, a co-operative study group from Germany collected, in 22 tertiary care centres over 10 years, 2504 patients with oral anticoagulation-related ICH, of whom 137 had mechanical heart valves.9 The authors studied the international normalized ratio (INR) at baseline which was, as expected, well within the target range. INR reversal was attempted in the management of ICH, but was unsuccessful in the majority of patients. Finally, the moment of restart of therapeutic anticoagulation, either parenteral, oral, or both, was studied in retrospect. Therapeutic anticoagulation was started in only 48% of patients. After anticoagulation resumption, bleeding occurred in 15% of cases within 50 days and was more common than thrombo-embolic events (5%). In comparison with no resumption, restart of anticoagulation resulted in a significant increase in bleeding (from 6% to 26%), but also in a reduction of thrombo-embolic events (from 10% to 2%). Of the bleeding events, ICH recurrence was the most common complication, and the majority of thrombo-embolic events were intracranial. The most interesting findings of the study, however, were the timing plots of bleeding on one hand and thrombo-embolism on the other. Resumption of therapeutic anticoagulation earlier than 14 days after ICH was associated with more bleeding compared with restart after 14 days, whereas the combination of bleeding and ischaemic complications was also in favour of anticoagulation resumption later than 14 days. These findings also agreed well with the final neurological outcome. The combination of timing of anticoagulation restart on one hand and the neurological recovery on the other is the centrepiece of the study. The authors must be complimented on their extensive and thorough work on the vexing issue of ICH in patients with a mechanical heart valve. In particular, the per 3 day balancing of the bleeding risk vs. the risk of thrombosis has been well worked out and illustrated. Also, the correction for treatment crossover was factored in. However, their work is not unique. In a previous systematic review on 88 cases of ICH in carriers of mechanical heart valves, no clear advice regarding restart of VKAs could be given.5 There has been another study that was reported as a letter, where there was no correction for treatment crossovers and no data on neurological outcome were given. In that study in 141 patients, the advice was that restart of anticoagulation was optimal between 7 and 10 days after ICH.6 In the current study, such a period proved to be too short and resulted in a worse neurological outcome. Yet, as pointed out by the authors, their data are observational and retrospective over 10 years. Such analyses have their inherent shortcomings. A randomized trial would be ideal, but ethically difficult to perform. The data from the current study will end up in future guidelines, but will not change them. In absolute numbers, VKA-related ICH is far more common in atrial fibrillation than in patients with a mechanic heart valve, and represents a huge problem. Clearly today’s data are not applicable for atrial fibrillation patients. Patients with atrial fibrillation who are not anticoagulated have a risk of thrombo-embolism similar to that of untreated patients with mechanical heart valves.10,11 Therefore, the large majority of patients with atrial fibrillation need oral anticoagulation, not the least because they have more co-morbidities leading to stroke, such as hypertension.12 For resumption of oral anticoagulation after ICH in atrial fibrillation, there are good data showing that restart should take place at 7–8 weeks after ICH.13 Not starting anticoagulation altogether or alternatively starting antiplatelet therapy in atrial fibrillation after ICH has a poor long-term mortality outcome.14 Unlike for carriers of mechanical heart valves, for atrial fibrillation patients there are effective alternatives to reduce the risk for ICH, such as the use of NOACs or the insertion of a left atrial appendage-occluding devices (Table 1). Although attractive, the efficacy and safety of these strategies are currently under investigation in randomized trials, but unfortunately these options are not applicable for patients with mechanical heart valves for the reasons mentioned above. Finally, replacing the mechanical valve by a bioprosthesis after ICH seems unattractive given the risk of reoperation in general, and the risk of recurrent ICH in the peri-procedural phase in particular. Table 1 Ongoing trials of alternative strategies in patients with atrial fibrillation and intracranial haemorrhage associated with oral anticoagulants Trial NCT Patients Intervention Control Primary endpoint APACHE-AF 02565693 100 Apixaban Antiplatelets or no antithrombotics Death or non-fatal stroke STROKECLOSE 02830152 750 LA occluder Antithrombotics or no antithrombotics Death, non-fatal stroke, or major bleeding Trial NCT Patients Intervention Control Primary endpoint APACHE-AF 02565693 100 Apixaban Antiplatelets or no antithrombotics Death or non-fatal stroke STROKECLOSE 02830152 750 LA occluder Antithrombotics or no antithrombotics Death, non-fatal stroke, or major bleeding LA, left atrial appendage; NCT, clinicaltrials.gov trial number. Table 1 Ongoing trials of alternative strategies in patients with atrial fibrillation and intracranial haemorrhage associated with oral anticoagulants Trial NCT Patients Intervention Control Primary endpoint APACHE-AF 02565693 100 Apixaban Antiplatelets or no antithrombotics Death or non-fatal stroke STROKECLOSE 02830152 750 LA occluder Antithrombotics or no antithrombotics Death, non-fatal stroke, or major bleeding Trial NCT Patients Intervention Control Primary endpoint APACHE-AF 02565693 100 Apixaban Antiplatelets or no antithrombotics Death or non-fatal stroke STROKECLOSE 02830152 750 LA occluder Antithrombotics or no antithrombotics Death, non-fatal stroke, or major bleeding LA, left atrial appendage; NCT, clinicaltrials.gov trial number. In conclusion, VKA-related ICH in patients with mechanical valves is not uncommon, and its optimal management remains problematic. Resumption of therapeutic anticoagulation can be postponed for at least 2 weeks, as can be learned from the extensive study in this issue. Conflict of interest: F.W.A.V. has received honoraria for consulting and presentations from Bayer HealthCare, Boehringer-Ingelheim, BMS/Pfizer, and Daiichi-Sankyo. References 1 Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; RE-LY Investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975– 998. Google Scholar CrossRef Search ADS PubMed 2 Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11– 17. Google Scholar CrossRef Search ADS PubMed 3 Ruff CT, Giugliano RP, Braunwald T, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955– 962. Google Scholar CrossRef Search ADS PubMed 4 Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2017; 38: 2739– 2791. Google Scholar CrossRef Search ADS PubMed 5 AlKherayf F, Xu Y, Gandara E, Westwick H, Moldovan ID, Wells PS. Timing of vitamin K antagonist re-initiation following intracranial hemorrhage in mechanical heart valves: systematic review and meta-analysis. Thromb Res 2016; 144: 152– 157. Google Scholar CrossRef Search ADS PubMed 6 Flint AC, Lingamneni R, Rao VA, Chan SL, Ren X, Pombra J, Hemphill JC3rd, Bonow RO. Risks of thrombosis and rehemorrhage during early management of intracranial hemorrhage in patients with mechanical heart valves. J Am Coll Cardiol 2015; 66: 1738– 1739. Google Scholar CrossRef Search ADS PubMed 7 Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O’Gara PT, Rigolin VH, Sundt TM3rd, Thompson A. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017; 135: e1159– e1195. Google Scholar CrossRef Search ADS PubMed 8 Halvorsen S, Storey RF, Rocca B, Sibbing D, Ten Berg J, Grove EL, Weiss TW, Collet JP, Andreotti F, Gulba DC, Lip GYH, Husted S, Vilahur G, Morais J, Verheugt FWA, Lanas A, Al-Shahi Salman R, Steg PG, Huber K. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2017; 38: 1455– 1462. Google Scholar PubMed 9 Kuramatsu JB, Sembill JA, Gerner ST, Sprügel MI, Hagen M, Roeder SS, Endres M, Haeusler KG, Sobesky J, Schurig J, Zweynert S, Bauer M, Vajkoczy P, Ringleb PA, Purrucker J, Rizos T, Volkmann J, Müllges W, Kraft P, Schubert AL, Erbguth F, Nueckel M, Schellinger PD, Glahn J, Knappe UJ, Fink GR, Dohmen C, Stetefeld H, Fisse AL, Minnerup J, Hagemann G, Rakers F, Reichmann H, Schneider H, Wöpking S, Ludolph AC, Stösser S, Neugebauer H, Röther J, Michels P, Schwarz M, Reimann G, Bäzner H, Schwert H, Classen J, Michalski D, Grau A, Palm F, Urbanek C, Wöhrle JC, Alshammari F, Horn M, Bahner D, Witte OW, Günther A, Hamann GF, Lücking H, Dörfler A, Achenbach S, Schwab S, Huttner HB. Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves. Eur Heart J 2018; 39: 1709– 1723. 10 Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89: 635– 641. Google Scholar CrossRef Search ADS PubMed 11 Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991; 84: 527– 539. CrossRef Search ADS PubMed 12 Bassand JP, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Ten Cate H, Turpie AG, Verheugt FW, Kakkar AK. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J 2016; 37: 2882– 2889. Google Scholar CrossRef Search ADS PubMed 13 Pennlert J, Overholser R, Asplund K, Carlberg B, Van Rompaye B, Wiklund PG, Eriksson M. Optimal timing of anticoagulant treatment after intracerebral hemorrhage in patients with atrial fibrillation. Stroke 2017; 48: 314– 320. Google Scholar CrossRef Search ADS PubMed 14 Nielsen PB, Larsen TB, Skjøth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation 2015; 132: 517– 525. Google Scholar CrossRef Search ADS PubMed Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: email@example.com. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/about_us/legal/notices)
European Heart Journal – Oxford University Press
Published: Mar 12, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera